Bank of America Securities Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Scholar Rock Holding today and set a price target of $50.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Ahmad is a 4-star analyst with an average return of 2.6% and a 52.93% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals.
In addition to Bank of America Securities, Scholar Rock Holding also received a Buy from H.C. Wainwright’s Andres Y. Maldonado in a report issued yesterday. However, on January 15, TipRanks – Google initiated coverage with a Hold rating on Scholar Rock Holding (NASDAQ: SRRK).
Based on Scholar Rock Holding’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $102.22 million. In comparison, last year the company had a GAAP net loss of $64.48 million
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year. Last month, Srinivas Akkaraju, a Director at SRRK bought 29,599.00 shares for a total of $1,181,633.67.
Read More on SRRK:
Disclaimer & DisclosureReport an Issue
- Raising Conviction on Scholar Rock: Dual Supply Chain and Broad Apitegromab Adoption Underpin Buy Rating and Higher Target
- Scholar Rock price target raised to $58 from $44 at H.C. Wainwright
- Scholar Rock price target raised to $50 from $49 at BofA
- Scholar Rock: Apitegromab Manufacturing Resolution and Pipeline Expansion Underpin Buy-Rated Risk-Reward Profile
- Scholar Rock Details 2026 Strategy and Regulatory Priorities
